secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001493152-24-021732
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway
--------------------------------------------------------------------------------

- Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.
- MannKind grants Pulmatrix exclusive Cricket device license for PUR3100 (DHE/migraine); non-exclusive for neurological disease.
- MannKind assumes Pulmatrix's Bedford R&D facility lease and equipment; expected close July 2024.
- CEO: transaction validates iSPERSE technology and extends cash runway into 2026.
- MannKind to provide development services under MSA and may hire some Pulmatrix R&D staff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224021732/0001493152-24-021732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224021732/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-021732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer